The board's competencies will be further strengthened in the investor relations field with his documented results and his passion for Danish small and midcap companies.  

In 2020, Tue Østergaard chose to leave the Norwegian investment bank ABG Sundal Collier. After nine years as investment manager and managing partner for the Danish department of ABG, he had helped establish the Norwegian bank in the Danish investment environment.

Following his departure from ABG Sundal Collier, he has engaged as an investor, founder, advisor, mentor, or board member in a string of companies with new, innovative technologies and business models. Furthermore, he has founded his own company HC Andersen Capital with a vision of creating visibility for companies in the stock market through enhanced digital investor relations tools and hereby with the purpose of democratizing visibility in the stock market dedicated for equities below the Danish C25-index.

Tue Østergaard comments:

- It is my ambition to be a mentor for young professionals and to get involved in industries I do not know in advance. I have a great passion for Danish small and midcap companies and want to use my energy, creativity, and curiosity to be part of new companies where I can influence business development. DanCann Pharma is a perfect match and I look forward to being a part of the ambitious Company's exiting and prosperous journey.

Carsten Trads, Chairman of the Board at DanCann Pharma, comments:

- We are extremely pleased that Tue has agreed to be nominated to our Board of Directors. With his many years of experience in executive leadership and board membership roles in companies such as HC Andersen Capital, GreenMobility A/S, ABG Sundal Collier and Nordea, he has the expertise needed to contribute to the further development of DanCann Pharma's business. Tue's appointment comes at the most opportune time for DanCann Pharma, as we are fully prepared to realize our commercialization strategy and are moving into the next phase, where we will benefit from Tue's years of experience and unique insights from financial markets.

- Jeppe and I have had a constructive dialogue for a long time about how we can best strengthen DanCann Pharma in the future. We have agreed - on Jeppe's initiative - that Jeppe in the future must focus on being CEO, where he can create the greatest value, and be fully dedicated. Having been a major contributor to DanCann Pharma throughout the Company's existence as a founder, major shareholder, and board member, Jeppe will now dedicate his time to leading the Company as CEO (and major shareholder) in close collaboration with the Board of Directors.

Jeppe Krog Rasmussen, Founder, CEO and Board Member at DanCann Pharma, comments:

- Going forward, I will work in a constellation 100% dedicated to the job as CEO of DanCann Pharma, while we create professionalism and balance between the board and the executive management team, and thereby the best decisions and initiatives for DanCann Pharma.

- I have personally nominated Tue to the Board of Directors, based on a good relationship, where Tue has attracted and inspired me, and I am absolutely sure that Tue will be a great contributor to the professionalized board, as well as a fantastic partner and mentor for me in relation to investor relations and general strategy.

- I warmly welcome Tue and I am sure that we will have a fantastic and exciting future together.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.
For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: jkr@dancann.com
Website: www.dancann.com